Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

34 results about "Propanoic Acid Derivatives" patented technology

Picolinamido-propanoic acid derivatives useful as glucagon receptor antagonists

The present invention is directed to picolanmido-propanoic acid derivatives, pharmaceutical compositions containing them and their use in the treatment and / or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
Owner:JANSSEN PHARMA NV

Vinylphenylpropionic acid derivatives, production process therefor, polymer thereof and radiation sensitive resin composition

Vinylphenylpropionic acid derivatives; processes for producing the derivatives; polymers of the same; and radiosensitive resin compositions containing the polymers. The above polymers exhibit low radiation absorption and are useful as the resin component of radiosensitive resin compositions particularly suitable for chemically amplified resists. For example, t-butyl 4-vinylphenylpropionate is produced by (1) reacting t-butyl bromoacetate with tri(n-butyl)phosphine to obtain a quaternary phosphonium salt, (2) reacting this salt with a base to obtain a phosphorus ylide, (3) reacting this ylide with 2,4,6-tris(3',5'-di-t-butyl-4'-hydroxybenzyl)methyl-styrene to obtain a quaternary phosphonium salt, and (4) hydrolyzing this salt.
Owner:JSR CORPORATIOON

2-(4-methoxyphenoxy) propionic acid derivative with sweetness inhibiting effect and industrial production method of 2-(4-methoxyphenoxy) propionic acid derivative

The invention discloses a 2-(4-methoxyphenoxy) propionic acid derivative with a sweetness inhibiting effect and an industrial production method of the 2-(4-methoxyphenoxy) propionic acid derivative. The structural general formula is shown in the specification, in the formula, R represents C1-C4 alkyl, C1-C4 alkoxy, nitryl or halogen atoms, and X represents hydrogen atoms or C1-C3 alkyl. The preparation method comprises the following steps: mixing p-methoxy substituted phenol, ethyl 2-bromoalkanoate and potassium carbonate, reacting in dimethylformamide, and filtering; adding water and an organic phase into the filtrate, carrying out liquid separation treatment, and evaporating to remove the organic phase to obtain an ester compound; and adding the obtained ester and sodium hydroxide into ethanol, carrying out reflux reaction, acidifying, extracting, recrystallizing and the like to obtain the 2-(4-methoxyphenoxy) propionic acid derivative. The derivative is a brand-new sweetness inhibiting compound and has a good sweetness inhibiting effect on cane sugar, the industrial method is mild in reaction condition, the temperature does not exceed 100 DEG C, separation and purification are simple, and the product purity is high.
Owner:SOUTH CHINA UNIV OF TECH

Propanoic acid derivatives that inhibit binding of integrins to their receptors

The present invention relates to methods of inhibiting the binding of α4β1 integrin to its receptors such as VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit such binding; pharmaceutically active compositions containing such compounds; and Use of such compounds in the above aspects or in preparations for controlling or preventing disease states in which α4β1 is involved.
Owner:ENCYSIVE PHARM INC NEW YORK NEW

Pyridine derivatives

ActiveUS20170362209A1Reduce urine productionIncrease endogenous AVP levelOrganic chemistryBlood disorderBacteriuriaMedicine
The problem to be solved by the present invention is to provide a compound suitable for a pharmaceutical composition, specifically an agent for treating nocturia.The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, would maintain and / or increase an endogenous AVP level to enhance the antidiuretic effect, which would contribute to a decreased number of nocturnal voids, and have extensively studied compounds which inhibit P-LAP. As a result, the inventors have found that (2R)-3-amino-2-(pyridylmethyl)-2-hydroxy-propanoic acid derivatives have excellent P-LAP inhibitory activity. The inventors have evaluated antidiuretic effects in water-loaded rats and have found that the compounds increase endogenous AVP levels by inhibiting P-LAP and consequently reduce urine production. The present invention therefore provides compounds expected to be used as an agent for treating nocturia based on P-LAP inhibition.
Owner:ASTELLAS PHARMA INC +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products